Training and professional career

Dr. Bellmunt graduated in Medicine and Surgery from the Autonomous University of Barcelona in 1982 and received his doctorate laude in 1989, at the same university. She completed her residency in Medical Oncology at the Vall d’Hebron Hospital in Barcelona. She completed her training by obtaining the European Certificate in Medical Oncology in London in 1989 and with stays in the Clinical Immunology Department, Division of Medical Oncology and Department of Immunopathology at memorial Sloan-Kettering Cancer Center in New York in 1987 and 1989. After completing her residency, she joined the Medical Oncology Service at Vall d’Hebron Hospital as head of the Urologic Unit. In January 2006 he was appointed Head of the Solid Tumours Section of the Medical Oncology Service of the Hospital del Mar in Barcelona. Since 2008 and as a result of his collaboration with the Dana Farber Cancer Institute (DFCI), until the end of 2012 he has been Visiting Professor at Harvard University, Boston. In 2013 he was appointed director of the Blader Cancer Clinic of the DFCI, Harvard, Boston (USA) and Associate Professor at Harvard Medical School. However, during his time as director of the Research Institute of the Hospital del Mar (IMIM 2016-2019) he was Professor of Medicine at the Pompeu Fabra University of Barcelona. He is currently the director of the Bladder Cancer Program at Beth Israel Deaconess in Boston maintaining his academic affiliation as an associate professor with Harvard Medical School.

Professional activity

His areas of interest in research are in genito-urinary clinical oncology, focused on the development of drugs aimed at new therapeutic targets and translational research in the field of immunotherapy and receptors of growth factors and angiogenesis, among others, as objectives in cancer therapy. He conducts international multicentre trials of new immunotherapic drugs in the treatment of prostate, kidney and bladder cancer. He has coordinated the intergroup study in advanced transitional cancer (EORTC 30987). He works in the clinical development of several new agents and combinations and is a member of the advisory board of numerous therapies in the fight against cancer. She is a member of the American Society for Cancer Research (AACR), the American Association of Clinical Oncology (ASCO), the European Association of Medical Oncology (ESMO) and the Spanish Society of Medical Oncology (SEOM). He participates as an expert advisor in the elaboration and development of the Oncoguies del CatSalut of the Generalitat de Catalunya. He is a member of the Scientific Committee of the American Congress of Clinical Oncology –Genitourinary (ASCO-GU) where he holds lectures and is a Faculty Member. He has been chairman of the Advanced Bladder Cancer Committee at the European Organization for Cancer Research and Treatment (EORTC) and consultant to the Genito-Urinary Group (EORTC-GU) since 2000. He is co-founder and has been president of the Spanish Genito-Urinary Tumour Treatment Group (SOGUG). However, he is Professor of Medicine at the Pompeu Fabra University of Barcelona and editorial advisor of the publications Journal of Clinical Oncology, Annals of Oncology, European Urology, European Journal of Cancer, British Journal of Urology Int. and Journal of Urology, among others. Dr. Joaquim Bellmunt has published more than 350 arbitration articles and more than 340 papers in congresses and book chapters.